On December 5, Walt Dyne (000915.SZ) stated on the investor interactive platform that Dyne Pharmaceutical products target children aged 1-3 and are administered rectally. They are suitable for children with fever caused by the common cold or influenza to relieve children with mild to moderate pain such as headache, arthralgia, migraine, toothache, muscle pain, and neuralgia in children.
华特达因(000915.SZ)：达因药业产品有针对1-3岁儿童，通过直肠给药
Walterdyne (000915.SZ): Dyne Pharmaceuticals products are aimed at children aged 1-3 and are administered rectally
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.